Drug Profile
Research programme: neuropsychiatric disorder therapeutics - Roche/SRI International
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Roche; SRI International
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in USA
- 12 Nov 2009 Preclinical trials in Cognition disorders in USA (unspecified route)